Welcome to our dedicated page for Opthea SEC filings (Ticker: CKDXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Opthea's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Opthea's regulatory disclosures and financial reporting.
Opthea Ltd ownership update: Regal Partners Funds Management Pty Limited and Regal Partners Limited report beneficial ownership of 45,215,626 Ordinary Shares, representing 3.31% of the class. The filing states shared voting and dispositive power over the 45,215,626 shares. Each American Depositary Share represents 8 Ordinary Shares.
Opthea Limited filed a Form 25 to remove its American Depositary Shares from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The securities are ADSs, each representing eight ordinary shares, previously listed on The Nasdaq Global Select Market. The notification was signed by Chief Executive Officer Jeremy Levin on November 10, 2025.
Opthea Limited filed a Form 6-K noting it issued a press release announcing its intention to voluntarily delist its American Depositary Shares from the Nasdaq Global Select Market.
The press release, dated October 29, 2025, is furnished as Exhibit 99.1 and is incorporated by reference into Opthea’s Form S-8 (File No. 333-251052). This notice focuses on the planned delisting of Opthea’s ADSs from Nasdaq as described in the press release.
Opthea Limited submitted a Form 6-K as a foreign private issuer, primarily to furnish a press release announcing the appointment of a new company secretary. The report lists this press release as Exhibit 99.1 and is signed on behalf of Opthea by Executive Officer Jeremy Levin.
Opthea Limited, a foreign private issuer, filed a Form 6-K for October 2025. The filing mainly furnishes a press release, listed as Exhibit 99.1, announcing that Opthea received an A$10.8 million R&D Tax Incentive, a government-related research and development benefit.
Opthea Limited (CKDXF) filed its Form 20-F describing a company without product revenues that continues development of biologic candidates including sozinibercept and OPT-302. Management disclosed that it has not obtained regulatory approval for any product candidate, has incurred significant losses, and expects to need additional capital to complete clinical development. The company may reformulate candidates to target VEGF-C/D; if reformulation is not viable directors may consider a return of capital and ceasing operations.
The report discloses a resolution of the Development Funding Agreement: DFA investors provided US$20.0 million and were issued equity equal to 9.99% fully diluted (136,661,003 ordinary shares), liens were released and the DFA terminated. As of August 30, 2025 the Group had US$19.3 million of cash and cash equivalents. Management concluded internal control over financial reporting was not effective as of June 30, 2025 due to errors in accounting for the Funding Agreement and investor options.